Ms. Fuller, you spoke about your work with diabetes and access to insulin. As you noted, some drug manufacturers have tried to withdraw the less expensive insulin in favour of more expensive alternatives. Fortunately, the Canadian drug agency proposed under the national pharmacare plan would negotiate the best prices possible and keep affordable options on the market. Do you feel that the new regulations proposed by the PMPRB would effectively limit manufacturers from making decisions that prevent patients living with diabetes from accessing the affordable drugs they need?
On December 11th, 2020. See this statement in context.